Last updated: February 19, 2026
This report analyzes Mexican patent application MX2011001328, focusing on its scope, claims, and the surrounding patent landscape. The patent, assigned to F. Hoffmann-La Roche AG, claims novel crystalline forms of bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor used in oncology.
What is the Subject of Patent MX2011001328?
Patent application MX2011001328, filed on February 11, 2011, and published on November 10, 2011, concerns specific crystalline forms of bevacizumab. Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A). By inhibiting VEGF-A, bevacizumab prevents tumor angiogenesis, the process by which tumors develop new blood vessels to sustain their growth and metastasis. The patent aims to protect novel solid forms of this therapeutic protein, which may offer advantages in terms of stability, manufacturability, or formulation compared to existing amorphous or less defined forms.
The core of the invention lies in identifying and characterizing specific polymorphic or crystalline states of bevacizumab. These distinct solid forms can impact the drug's physical and chemical properties, influencing its shelf life, solubility, dissolution rate, and overall bioavailability. Protecting these specific forms can extend market exclusivity beyond the initial patent on the bevacizumab molecule itself.
What are the Key Claims of the Patent?
The patent application outlines several claims related to these novel crystalline forms of bevacizumab. While the precise wording and number of granted claims can evolve through the examination process, the typical scope of such applications focuses on:
- Specific Crystalline Forms: Claims will identify and define particular crystalline polymorphs of bevacizumab. This definition usually relies on characteristic analytical data, such as X-ray powder diffraction (XRPD) patterns, differential scanning calorimetry (DSC) thermograms, or infrared (IR) spectroscopy. For example, a claim might specify a bevacizumab crystalline form exhibiting a particular XRPD peak at a specific 2-theta angle.
- Pharmaceutical Compositions: Claims often extend to pharmaceutical compositions containing these specific crystalline forms. This includes formulations designed for parenteral administration, such as intravenous infusion. These compositions may also include pharmaceutically acceptable excipients.
- Methods of Manufacturing: Claims can also cover methods for producing these specific crystalline forms. This might involve controlled crystallization processes under specific temperature, solvent, and concentration conditions.
- Methods of Treatment: Dependent on the patent strategy and the strength of the data, claims might also be directed towards methods of treating specific diseases, such as various types of cancer (e.g., colorectal cancer, non-small cell lung cancer, glioblastoma), using the claimed crystalline forms or compositions.
The patent language will be precise, using scientific terminology to define the claimed entities and their properties. The inventive step in this context is often the discovery of a novel and advantageous solid form of a known active pharmaceutical ingredient.
How is Bevacizumab Typically Formulated and Administered?
Bevacizumab, marketed as Avastin by Roche, is primarily administered intravenously. The approved formulations are typically sterile liquid solutions designed for dilution and subsequent infusion. These formulations aim to maintain the stability and biological activity of the monoclonal antibody.
Key aspects of bevacizumab formulation include:
- Protein Stability: Monoclonal antibodies are large, complex proteins susceptible to degradation through various pathways, including aggregation, deamidation, and oxidation. Formulations are designed to prevent these changes.
- Excipients: Common excipients in antibody formulations include buffering agents (e.g., phosphates, citrates) to control pH, stabilizers (e.g., sugars like trehalose, amino acids like arginine), and surfactants (e.g., polysorbates) to prevent aggregation and adsorption to surfaces.
- Concentration: Bevacizumab is typically supplied in concentrations of 100 mg/4 mL and 400 mg/16 mL solutions, allowing for different dosing regimens based on patient weight and disease indication.
- Sterility and Pyrogenicity: As an injectable drug, all formulations must be sterile and free from pyrogenic substances to prevent adverse reactions.
The invention claimed in MX2011001328 suggests that crystalline forms of bevacizumab could offer an alternative or complementary approach to current liquid formulations, potentially impacting aspects like long-term storage stability, ease of reconstitution, or even enabling different administration routes if solubility and absorption characteristics are favorably altered in solid forms.
What is the Patent Landscape for Bevacizumab in Mexico?
The patent landscape for bevacizumab in Mexico is complex, involving the original patents covering the molecule and its therapeutic uses, as well as potential secondary patents on manufacturing processes, formulations, and new forms.
The primary innovator patent for bevacizumab would have covered the molecule itself and its initial indications. This patent's expiry in various jurisdictions has opened the door for biosimilar competition. However, secondary patents, such as those claiming specific crystalline forms or novel formulations, can create additional layers of intellectual property protection that may extend market exclusivity for the innovator.
Key elements of the bevacizumab patent landscape in Mexico relevant to MX2011001328 include:
- Original Compound Patents: Patents covering the bevacizumab protein sequence and its fundamental therapeutic utility would have been the initial basis for market exclusivity. These patents have likely expired or are nearing expiration in Mexico.
- Formulation Patents: Roche would have filed patents on the specific liquid formulations of Avastin. These patents may also be expiring or expired, but they can influence the types of generic or biosimilar products that can be launched.
- Process Patents: Patents claiming specific methods for producing bevacizumab, including fermentation and purification processes, are also part of the landscape.
- New Form Patents (like MX2011001328): The patent application MX2011001328 represents an effort to secure additional protection by claiming novel crystalline forms. If granted and maintained, such patents can:
- Prevent biosimilar manufacturers from using the specific crystalline form claimed, even if the original compound patent has expired.
- Require biosimilar manufacturers to develop their own crystalline forms or formulations that do not infringe on these secondary patents.
- Potentially lead to "evergreening" strategies, where a company seeks to extend patent protection by patenting minor variations or improvements on an existing drug.
The Mexican Institute of Industrial Property (IMPI) is responsible for examining and granting patents in Mexico. The examination process for patent application MX2011001328 would have assessed novelty, inventive step, and industrial applicability, comparing it against existing prior art.
What are the Potential Implications of Patent MX2011001328 for Biosimilar Developers?
If patent application MX2011001328 is granted and its claims are upheld, it could have significant implications for companies seeking to develop and market biosimilar versions of bevacizumab in Mexico.
Potential implications include:
- Infringement Risk: Biosimilar developers must carefully analyze the granted claims of MX2011001328. If their proposed crystalline form of bevacizumab falls within the scope of a granted claim, they would be at risk of infringing on Roche's patent rights. This would necessitate developing an alternative crystalline form or formulation that does not infringe.
- Development Strategy: The existence of patents on specific crystalline forms can force biosimilar developers to invest more resources in developing unique crystalline forms or alternative manufacturing processes. This can increase development timelines and costs.
- Market Entry Timing: The lifespan of secondary patents can influence the timeline for biosimilar market entry. If MX2011001328 is granted with a term that extends beyond the expiry of the primary bevacizumab patents, it could delay the introduction of biosimilars utilizing the patented crystalline form.
- Licensing or Litigation: Biosimilar developers might consider seeking a license for the patented crystalline form from Roche. Alternatively, they might challenge the validity of the patent through administrative proceedings or litigation if they believe it is not enforceable.
- Data Requirements: Regulatory agencies in Mexico (likely COFEPRIS for pharmaceutical products) will require biosimilar manufacturers to demonstrate biosimilarity to the reference product (Avastin). If a biosimilar uses a different crystalline form, it may require additional analytical and clinical data to establish comparability.
The granting of this patent would therefore add a layer of complexity to the biosimilar market entry strategy for bevacizumab in Mexico, requiring careful IP due diligence and strategic planning.
What is the Status of Bevacizumab Biosimilars in Mexico?
The market for bevacizumab biosimilars in Mexico is developing. As the innovator patent protection for the bevacizumab molecule itself diminishes, opportunities for biosimilar entry increase.
Key aspects of the bevacizumab biosimilar landscape in Mexico:
- Regulatory Framework: Mexico has established a regulatory framework for biosimilars, enabling their approval and market entry. This framework requires rigorous demonstration of biosimilarity to the reference medicinal product.
- Approved Biosimilars: Several bevacizumab biosimilars have been approved and launched in Mexico by various pharmaceutical companies. These products offer more affordable treatment options for patients. Examples may include products from companies like Sandoz, Pfizer (through Hospira acquisition), and others.
- Market Competition: The presence of approved biosimilars indicates active competition in the Mexican market. This competition drives down prices and increases patient access to bevacizumab therapy.
- Patent Challenges: As with any biosimilar market, patent litigation and challenges are common. Biosimilar companies often challenge the validity of secondary patents, such as formulation or crystalline form patents, to clear the path for their product launches.
- Impact of Secondary Patents: The success and impact of secondary patents like MX2011001328 will depend on their granted scope, their enforceability in Mexican courts, and the strategies adopted by biosimilar manufacturers. A strong granted patent on a distinct and advantageous crystalline form could influence the market dynamics for specific biosimilar products.
The ongoing development of the biosimilar market for bevacizumab highlights the importance of understanding the complete patent landscape, including both primary and secondary patents, for strategic decision-making.
How Might Roche Leverage Patent MX2011001328?
Roche, as the assignee of patent application MX2011001328, may leverage this intellectual property in several ways to protect its market position for bevacizumab in Mexico.
Leveraging strategies include:
- Extending Market Exclusivity: The primary objective of patenting new crystalline forms is to extend the period of market exclusivity beyond the expiration of the original bevacizumab compound patent. This is particularly important in the context of biosimilar competition.
- Deterring Biosimilar Entry: A granted patent on a specific crystalline form can act as a significant barrier to entry for biosimilar manufacturers. It forces biosimilar developers to either design around the patent (i.e., develop a non-infringing form) or face potential litigation.
- Establishing a Premium Product: If the crystalline form offers demonstrable advantages over existing formulations (e.g., enhanced stability, easier handling, or improved bioavailability), Roche could potentially market it as a next-generation or premium product, even if the underlying molecule is off-patent.
- Licensing Opportunities: Roche could potentially license the patented crystalline form to other pharmaceutical companies, generating royalty revenue. This is less common for innovator companies seeking to maintain a competitive edge but could be a consideration in specific market scenarios.
- Enforcement and Litigation: Should a biosimilar manufacturer launch a product that infringes on the granted claims, Roche would have grounds to pursue legal action, seeking injunctions and damages.
- Strategic Defense: The patent can be used as a defensive asset. In the event of a patent dispute initiated by a biosimilar company challenging other Roche patents, the crystalline form patent could be used as leverage.
The specific strategy Roche employs will depend on its commercial objectives, the competitive landscape, and the strength and breadth of the granted claims.
Key Takeaways
- Patent application MX2011001328 filed by F. Hoffmann-La Roche AG claims novel crystalline forms of bevacizumab, a critical oncology drug.
- The patent's claims likely define specific solid-state properties of bevacizumab and potentially associated pharmaceutical compositions and manufacturing methods.
- This patent represents a potential secondary intellectual property layer intended to extend market exclusivity for bevacizumab beyond the expiry of its original composition-of-matter patent.
- If granted, MX2011001328 can significantly impact biosimilar developers in Mexico by posing infringement risks and necessitating alternative development strategies.
- Mexico has a regulatory pathway for biosimilars, and several bevacizumab biosimilars are already approved and marketed, intensifying competition.
- Roche can leverage this patent for market exclusivity extension, deterrence of biosimilars, and potentially as a basis for litigation or licensing.
FAQs
What is the filing date of patent application MX2011001328?
The filing date of patent application MX2011001328 is February 11, 2011.
Who is the assignee of patent application MX2011001328?
The assignee of patent application MX2011001328 is F. Hoffmann-La Roche AG.
What is the primary therapeutic use of bevacizumab?
Bevacizumab is used in oncology to treat various cancers by inhibiting tumor angiogenesis.
What type of intellectual property does patent MX2011001328 cover?
Patent MX2011001328 covers novel crystalline forms of bevacizumab.
How does a patent on a crystalline form differ from a patent on the drug molecule itself?
A patent on a crystalline form protects a specific solid-state structure of a known drug molecule, offering protection that can extend beyond the expiry of the original patent on the molecule itself.
Citations
[1] Mexican Institute of Industrial Property (IMPI). (n.d.). Patent Database Search. Retrieved from [IMPI website - exact URL for database search functionality would be required, but this is a placeholder for the official search portal.]
[2] F. Hoffmann-La Roche AG. (2011). Patent Application MX2011001328. Mexican Institute of Industrial Property.
[3] U.S. Food and Drug Administration (FDA). (n.d.). Bevacizumab (Avastin). Retrieved from [FDA drug information portal - specific URL for bevacizumab monograph.]
[4] Mexican Federal Commission for Protection from Sanitary Risks (COFEPRIS). (n.d.). Pharmaceuticals and Biologics Information. Retrieved from [COFEPRIS website - relevant section for biosimilar approvals.]
